Publications

At Ichnos Sciences, we’re working to make real progress in science and medicine. Explore our recent publications to discover how we’re shifting medicine forward. 

Date
Subject: All
All BEAT® Antibody Engineering Platform Cell Line Development ISB 1342 ISB 1442 ISB 2001 ISB 830
Title Lead Author Journal
06/10/2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies (PDF) Sammicheli S. et al. Presentation during EHA2022
04/13/2022 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of CD38+ Malignancies (PDF) Sammicheli S. et al. American Association for Cancer Research Annual Meeting
12/10/2021 ISB 1442 Preclinical Data Summary: First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for Relapsed / Refractory Multiple Myeloma (PDF) Sammicheli S. et al. Presentation at the American Society of Hematology Annual Meeting
11/04/2021 ISB 1442 ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma Sammicheli S. et al. American Society of Hematology Annual Meeting
06/04/2021 ISB 1342 ISB 1342: A First-In-Class CD38 T Cell Engager for the Treatment of Relapsed Refractory Multiple Myeloma (PDF) Doucey, M. 2021 ASCO Annual Meeting
05/03/2021 ISB 830 Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 Weeks Sher, L. 2021 Society for Investigative Dermatology Virtual Meeting
01/28/2021 Cell Line Development Generation of homogeneous cell populations with tunable levels of transgene expression (PDF) Schlicht D. et al. Journal of Biotechnology
05/13/2020 BEAT® Antibody Engineering Platform A single mutation increases heavy-chain heterodimer assembly of bispecific antibodies by inducing structural disorder in one homodimer species Stutz C. et al. Journal of Biological Chemistry
09/12/2019 BEAT® Antibody Engineering Platform Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development Ollier R. et al. mAbs
02/06/2019 ISB 830 GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis Guttman-Yassky E. et al. Journal of Allergy and Clinical Immunology

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.